PE20091057A1 - Antagonistas del receptor mineralcorticoide y metodos de uso - Google Patents
Antagonistas del receptor mineralcorticoide y metodos de usoInfo
- Publication number
- PE20091057A1 PE20091057A1 PE2008002008A PE2008002008A PE20091057A1 PE 20091057 A1 PE20091057 A1 PE 20091057A1 PE 2008002008 A PE2008002008 A PE 2008002008A PE 2008002008 A PE2008002008 A PE 2008002008A PE 20091057 A1 PE20091057 A1 PE 20091057A1
- Authority
- PE
- Peru
- Prior art keywords
- oxepin
- iliden
- dibenzo
- methyl
- mineralcorticoid receptor
- Prior art date
Links
- 239000002395 mineralocorticoid Substances 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
- -1 IMIDAZOL-2 (3H) -YLIDENE Chemical class 0.000 abstract 1
- XZMCDFZZKTWFGF-NJFSPNSNSA-N aminoformonitrile Chemical compound N#[14C]N XZMCDFZZKTWFGF-NJFSPNSNSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE DIBENZO[b,e]OXEPIN DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO H O F; L ES -(CH2)2-, -CH(CH3)-CH2- O UN ENLACE DIRECTO; R3 ES UN COMPUESTO DE FORMULA (i), (ii), (iii), ENTRE OTROS; R4 ES CN O -C(O)NH2. SON COMPUESTOS PREFERIDOS: (E)-N-(5-((E)-3-FLUORO-6H-DIBENZO[b,e]OXEPIN-11-ILIDENMETIL)-1-(1-METIL-AZETIDIN-3-IL)-1,3-DIHIDRO-BENZOIMIDAZOL-2-ILIDEN)-CIANAMIDA, (E)-N-(5-((E)-(3-FLUORODIBENZO[b,e]OXEPIN-11(6H)-ILIDEN)METIL)-1-((3S,4S)-4-HIDROXI-1-METILPIRROLIDIN-3-IL)-1H-BENZO[d]IMIDAZOL-2(3H)-ILIDEN)CIANAMIDA, (E)-N-[5-((E)-3-FLUORO-6H-DIBENZO[b,e]OXEPIN-11-ILIDENMETIL)-1-((3S,4S)-4-HIDROXI-1-METIL-PIRROLIDIN-3-IL)-1,3-DIHIDRO-BENZOIMIDAZOL-2-ILIDEN]-UREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR MINERALCORTICOIDE SIENDO UTILES EN EL TRATAMIENTO DE NEFROPATIA DIABETICA, ENFERMEDAD RENAL CRONICA, ARRITMIA MIOCARDIAL, HIPERALDOSTERONISMO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1477607P | 2007-12-19 | 2007-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091057A1 true PE20091057A1 (es) | 2009-07-20 |
Family
ID=40430143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008002008A PE20091057A1 (es) | 2007-12-19 | 2008-12-02 | Antagonistas del receptor mineralcorticoide y metodos de uso |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7994164B2 (es) |
| EP (2) | EP2537845B1 (es) |
| JP (1) | JP5562866B2 (es) |
| KR (1) | KR101254382B1 (es) |
| CN (1) | CN101903377B (es) |
| AR (1) | AR069554A1 (es) |
| AU (1) | AU2008343524B2 (es) |
| BR (1) | BRPI0820805A2 (es) |
| CA (1) | CA2710409C (es) |
| CL (1) | CL2008003600A1 (es) |
| CO (1) | CO6300953A2 (es) |
| DK (1) | DK2235007T3 (es) |
| DO (1) | DOP2010000185A (es) |
| EA (1) | EA017668B1 (es) |
| EC (2) | ECSP10010266A (es) |
| ES (2) | ES2459318T3 (es) |
| GT (1) | GT201000179A (es) |
| HR (1) | HRP20120916T1 (es) |
| IL (1) | IL206353A (es) |
| MA (1) | MA31910B1 (es) |
| MX (1) | MX2010006911A (es) |
| MY (1) | MY150474A (es) |
| NZ (1) | NZ586300A (es) |
| PE (1) | PE20091057A1 (es) |
| PL (1) | PL2235007T3 (es) |
| PT (1) | PT2235007E (es) |
| RS (1) | RS52594B (es) |
| SI (1) | SI2235007T1 (es) |
| TN (1) | TN2010000292A1 (es) |
| TW (1) | TWI431010B (es) |
| UA (1) | UA100131C2 (es) |
| WO (1) | WO2009085584A1 (es) |
| ZA (1) | ZA201004257B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| CA2708324C (en) | 2007-12-19 | 2013-03-05 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| ES2542001T3 (es) * | 2009-03-12 | 2015-07-29 | Eli Lilly And Company | Antagonista de receptor de mineralocorticoides y procedimientos de uso |
| WO2011141456A1 (en) | 2010-05-10 | 2011-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| EP2582365B1 (en) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
| CN102060670A (zh) * | 2011-01-04 | 2011-05-18 | 常州大学 | 一种2-溴-6-氟苯甲醇的制备方法 |
| MA38559B1 (fr) | 2013-05-02 | 2018-04-30 | Pfizer | Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10 |
| AR099416A1 (es) | 2014-02-28 | 2016-07-20 | Lilly Co Eli | Terapia combinada para la hipertensión resistente |
| UY36195A (es) | 2014-06-30 | 2016-01-08 | Astrazeneca Ab | Amidas de benzoxazinona como reguladores del receptor mineralocorticoide |
| BR112017007112A2 (pt) * | 2014-11-21 | 2017-12-26 | Lilly Co Eli | compostos de 1,2-benzotiazol para o tratamento de distúrbios renais |
| ES2846835T3 (es) | 2015-10-13 | 2021-07-29 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea |
| ES2973248T3 (es) | 2016-07-26 | 2024-06-19 | Inst Nat Sante Rech Med | Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis |
| UA123464C2 (uk) * | 2016-09-24 | 2021-04-07 | Кейбіпі Байосайєнсіз Ко., Лтд. | Фармацевтична композиція, яка містить антагоніст мінералокортикоїдних рецепторів, та її застосування |
| US20230151425A1 (en) | 2020-03-11 | 2023-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| US20240366632A1 (en) | 2021-08-31 | 2024-11-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of ocular rosacea |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072756A (en) * | 1973-05-17 | 1978-02-07 | Sandoz Ltd. | Tricyclo piperidino ketones and soporific compositions thereof |
| SE426341C (sv) * | 1980-02-14 | 1985-09-23 | Fagersta Ab | Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser |
| FR2603713B1 (fr) * | 1986-09-10 | 1992-07-24 | Canon Kk | Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant |
| CA1338625C (en) * | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| GB8914061D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| US5378701A (en) * | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
| US6372779B1 (en) | 1997-12-29 | 2002-04-16 | Ortho Pharmaceutical Corporation | Anti-inflammatory compounds |
| EP1154997A4 (en) | 1999-01-26 | 2002-11-04 | Dana Farber Cancer Inst Inc | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE |
| BR0213633A (pt) * | 2001-11-21 | 2004-08-24 | Millennium Pharm Inc | Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos |
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| PL1697350T3 (pl) * | 2003-12-19 | 2008-11-28 | Lilly Co Eli | Modulatory receptorów jądrowych dla tricyklicznych hormonów steroidowych |
| US7482344B2 (en) | 2003-12-19 | 2009-01-27 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| JP2008508314A (ja) | 2004-07-28 | 2008-03-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物 |
| US20060116382A1 (en) | 2004-11-10 | 2006-06-01 | Wenqing Yao | Lactam compounds and their use as pharmaceuticals |
| RS20090208A (en) | 2006-10-31 | 2010-06-30 | Pfizer Products Inc. | Pyrazoline compounds as mineralocorticoid receptor antagonists |
| EP2142194A1 (en) | 2007-03-29 | 2010-01-13 | N.V. Organon | Mineralocorticoid receptor antagonists |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| US20100292233A1 (en) | 2008-01-25 | 2010-11-18 | Arena Pharmaceuticals, Inc. | Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists |
| ES2542001T3 (es) | 2009-03-12 | 2015-07-29 | Eli Lilly And Company | Antagonista de receptor de mineralocorticoides y procedimientos de uso |
-
2008
- 2008-12-02 PE PE2008002008A patent/PE20091057A1/es not_active Application Discontinuation
- 2008-12-02 TW TW097146779A patent/TWI431010B/zh not_active IP Right Cessation
- 2008-12-03 CL CL2008003600A patent/CL2008003600A1/es unknown
- 2008-12-03 AR ARP080105263A patent/AR069554A1/es unknown
- 2008-12-09 RS RS20120541A patent/RS52594B/en unknown
- 2008-12-09 EP EP12185389.9A patent/EP2537845B1/en active Active
- 2008-12-09 WO PCT/US2008/085997 patent/WO2009085584A1/en active Application Filing
- 2008-12-09 CA CA2710409A patent/CA2710409C/en not_active Expired - Fee Related
- 2008-12-09 EA EA201070762A patent/EA017668B1/ru not_active IP Right Cessation
- 2008-12-09 MY MYPI20102867 patent/MY150474A/en unknown
- 2008-12-09 BR BRPI0820805-0A patent/BRPI0820805A2/pt not_active IP Right Cessation
- 2008-12-09 KR KR1020107013601A patent/KR101254382B1/ko not_active Expired - Fee Related
- 2008-12-09 UA UAA201007627A patent/UA100131C2/uk unknown
- 2008-12-09 HR HRP20120916AT patent/HRP20120916T1/hr unknown
- 2008-12-09 MX MX2010006911A patent/MX2010006911A/es active IP Right Grant
- 2008-12-09 ES ES12185389.9T patent/ES2459318T3/es active Active
- 2008-12-09 ES ES08866835T patent/ES2396605T3/es active Active
- 2008-12-09 SI SI200830852T patent/SI2235007T1/sl unknown
- 2008-12-09 JP JP2010539618A patent/JP5562866B2/ja not_active Expired - Fee Related
- 2008-12-09 PL PL08866835T patent/PL2235007T3/pl unknown
- 2008-12-09 US US12/330,539 patent/US7994164B2/en not_active Expired - Fee Related
- 2008-12-09 EP EP08866835A patent/EP2235007B1/en active Active
- 2008-12-09 CN CN200880121527.2A patent/CN101903377B/zh not_active Expired - Fee Related
- 2008-12-09 NZ NZ586300A patent/NZ586300A/en not_active IP Right Cessation
- 2008-12-09 PT PT88668355T patent/PT2235007E/pt unknown
- 2008-12-09 DK DK08866835.5T patent/DK2235007T3/da active
- 2008-12-09 AU AU2008343524A patent/AU2008343524B2/en not_active Ceased
-
2010
- 2010-06-14 IL IL206353A patent/IL206353A/en not_active IP Right Cessation
- 2010-06-14 MA MA32909A patent/MA31910B1/fr unknown
- 2010-06-15 ZA ZA2010/04257A patent/ZA201004257B/en unknown
- 2010-06-16 CO CO10072532A patent/CO6300953A2/es not_active Application Discontinuation
- 2010-06-17 EC EC2010010266A patent/ECSP10010266A/es unknown
- 2010-06-17 GT GT201000179A patent/GT201000179A/es unknown
- 2010-06-17 DO DO2010000185A patent/DOP2010000185A/es unknown
- 2010-06-18 TN TN2010000292A patent/TN2010000292A1/fr unknown
-
2012
- 2012-07-17 EC ECSP12012048 patent/ECSP12012048A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091057A1 (es) | Antagonistas del receptor mineralcorticoide y metodos de uso | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| PE20081467A1 (es) | Compuestos de benzoil amino heterociclico como mediadores de glucoquinasas (glk) | |
| PE20090610A1 (es) | Derivados de pirazol sustituidos | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| JP2011507868A5 (es) | ||
| PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
| PE20081659A1 (es) | Agonistas de gpcr | |
| PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20081532A1 (es) | Compuestos novedosos | |
| PE20110679A1 (es) | Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv | |
| PE20070187A1 (es) | Moduladores de lxr basados en pirazol | |
| PE20081884A1 (es) | Inhibidores heterociclicos de la aspartil proteasa | |
| PE20091042A1 (es) | Ligandos de oxadiazol del receptor metabotropico del glutamato y su uso como potenciadores - 841 | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
| PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
| PE20090369A1 (es) | Nuevos indazoles sustituidos, su preparacion y su utilizacion en terapeutica | |
| PE20070585A1 (es) | Derivados de sulfonamida como activadores de glucoquinasa | |
| PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
| PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
| PE20110067A1 (es) | Derivados de piperidina como inhibidores de renina | |
| PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20090875A1 (es) | Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |